CAS 571170-77-9

Laropiprant

Description:

Laropiprant is a chemical compound primarily known for its role as a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1). It is often studied in the context of cardiovascular health, particularly in relation to its potential to enhance the efficacy of certain lipid-lowering therapies, such as niacin. Laropiprant is characterized by its ability to mitigate the flushing side effects commonly associated with niacin, thereby improving patient compliance. The compound has a molecular formula that reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. Laropiprant is typically administered in oral form and has been evaluated in clinical trials for its safety and effectiveness. However, its use has been scrutinized due to concerns regarding its overall benefit-risk profile, leading to limited approval in certain markets. As with many pharmaceutical agents, understanding its mechanism of action, pharmacokinetics, and potential interactions with other medications is crucial for its application in therapeutic settings.

Formula: C₂₁H₁₉ClFNO₄S

InChI: InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1

InChI key: InChIKey=NXFFJDQHYLNEJK-CYBMUJFWSA-N

SMILES: C(N1C=2C(C3=C1[C@@H](CC(O)=O)CC3)=CC(F)=CC2S(C)(=O)=O)C4=CC=C(Cl)C=C4

Synonyms:

• (3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)cyclopent[b]indole-3-acetic acid
• (R)-2-(4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
• 2-[(3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid
• Cardaptive
• Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)-
• Mk-0524
• [(3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
• Laropiprant
• Laropiprant(MK0524)
• Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)-Laropiprant
• MK-0524(Laropiprant)/
• (3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)cyclopent[b]indole-3-acetic acid Laropiprant MK 0524
• CS-623
• Laropiprant, >=99%

MK 0524

CAS: 571170-77-9

Formula: C₂₁H₁₉ClFNO₄S

Purity: 98%

Color and Shape: Solid

Molecular weight: 435.8963

Ref: IN-DA00ECDW

Laropiprant

CAS: 571170-77-9

Laropiprant

Purity: ≥98%

Molecular weight: 435.9g/mol

Ref: 54-BUP12559

Laropiprant

CAS: 571170-77-9

Formula: C₂₁H₁₉ClFNO₄S

Color and Shape: Off-White Solid

Molecular weight: 435.91

Ref: 4Z-L-371

Laropiprant

CAS: 571170-77-9

Ref: 7W-GK4295

Laropiprant

CAS: 571170-77-9

Laropiprant is a drug that is designed to lower the levels of LDL cholesterol in the blood. It has been shown to be effective for long-term use and has metabolic effects with limited side effects. Laropiprant lowers LDL cholesterol by decreasing the production of prostaglandin J2 and increasing the excretion of bile acids, which are produced as a result of increased camp levels. The enzyme responsible for hepatic glucuronidation is inhibited by laropiprant, which leads to increased levels of its active form. Laropiprant also inhibits atherosclerosis through an in vitro method that involves human macrophages.

Formula: C₂₁H₁₉ClFNO₄S

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 435.9 g/mol

Ref: 3D-FC75279

Laropiprant

CAS: 571170-77-9

Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki

Formula: C₂₁H₁₉ClFNO₄S

Purity: 98.24% - 99.89%

Color and Shape: Solid

Molecular weight: 435.9

Ref: TM-T15712